Release Date: 30/05/18 10:49 Summary: Australian Capture Program Driving Sales Momentum Price Sensitive: Yes Download Document 1.2MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%